Zevalin Data to be Presented at ASH 2008
(Nasdaq and MTA: CTIC) today announced presentations or posters of interest
related to Zevalin(R) (ibritumomab tiuxetan) to be presented at the 50th
Annual Meeting of the American Society of Hematology (ASH),
in
In addition,
in a panel hosted by Biotechnology Industry Organization and Gerson Lehrman
Group(R), “Gerson Lehrman Group Innovators: Non-Hodgkin’s Lymphoma,” on
CTI and Spectrum announced on
into an agreement to form a joint venture, RIT Oncology LLC, to commercialize
and develop Zevalin in
Presentation/
Date/Time Abstract # Poster # Title
Saturday,
Dec. 6, 2008
5:30-7:30 PM 1144 Poster I-249 Radioimmunotherapy (90Y-
Zevalin(R)) Combined with
BEAM Conditioning Regimen and
Autologous Stem Cell
Transplantation for the
Treatment of Non Hodgkin
Lymphomas: Results of An
Italian Multicenter Study
Sunday
Dec. 7, 2008
6:00-8:00 PM 1959 Poster II-53 Radioimmunotherapy with
Yttrium-90-Ibritumomab
Tiuxetan as Part of a Reduced
Intensity Conditioning
Regimen for Allogeneic
Hematopoietic Cell
Transplantation in Patients
with Advanced Indolent Non-
Hodgkin Lymphoma: Interim
Analysis of a Phase II Study
Sunday
Dec. 7, 2008
6:00-8:00 PM 2001 Poster II-95 Phase II Study of Short
Course CHOP-Rituximab
Followed by 90-Y Ibritumomab
Tiuxetan as First-Line
Treatment for Follicular
Lymphoma: An Update and
Extension of Preliminary
Findings on Predictors of
Relapse
Sunday
Dec. 7, 2008 2002 Presentation Extended Follow-up of the
(10:35 AM) International Randomized
Poster II-96 Phase 3 First-Line Indolent
(9:30-11:00 AM) Trial (FIT) Shows Durable
Benefit of 90 Y-Ibritumomab
Tiuxetan (Zevalin(R))
Consolidation of First
Remission in Advanced Stage
Follicular Non-Hodgkin's
Lymphoma
Sunday
Dec. 7, 2008
6:00-8:00 PM 2158 Poster II-252 Monitoring of Post-Transplant
Hematopoiesis in Patients
Receiving High-Dose Yttrium-
90-Ibritumomab Tiuxetan
(Zevalin(R)) with Autograft:
Lack of Detection of
Remarkable Abnormalties.
Sunday
Dec. 7, 2008
6:00-8:00 PM 2187 Poster II-281 Red Marrow Dosimetry and Stem
Cell Reinfusion in High Dose
90Y-Ibritumomab Tiuxetan
Sunday
Dec. 7, 2008
6:00-8:00 PM 2995 Poster III-77 Dose Escalated
Radioimmunotherapy with
Yttrium-90-Ibritumomab
Tiuxetan as Part of a Reduced
Intensity Conditioning
Regimen for Allogeneic
Hematopoietic Cell
Transplantation in Patients
with Advanced Aggressive Non-
Hodgkin Lymphoma: An Interim
Analysis of a Phase I/II
Study
Monday,
Dec. 8, 2008
5:30-7:30 PM 3056 Poster III-138 R-FND Followed by
Radioimmunotherapy for High-
Risk Follicular Lymphoma
Monday,
Dec. 8, 2008
5:30-7:30 PM 3598 Poster III-680 Effect of Adding Ibritumomab
Tiuxetan (Zevalin)
Radioimmunotherapy
Consolidation to Three Cycles
of CHOP Plus Involved-Field
Radiotherapy for Limited-
Stage Aggressive Diffuse B-
Cell Lymphoma (SWOG 0313)
Monday,
Dec. 8, 2008
5:30-7:30 PM 3061 Poster III-143 90y Ibritumomab Tiuxetan as
Initial Treatment for
Follicular Lymphoma (ZEUS
Protocol). An Italian
Cooperative Study Group
Monday,
Dec. 8, 2008
5:30-7:30 PM 3063 Poster III-145 Efficacy of 90 Y -
Ibritumomab Tiuxetan in
Relapsed or Refractory
Primary Gastric Non Hodgkin's
Lymphoma
Monday,
Dec. 8, 2008
5:30-7:30 PM 3064 Poster III-146 Radioimmunotherapy Is Safe
and Effective in Relapse
after Stem Cell
Transplantation
For more information about the ASH annual meeting and for a complete list
of abstracts, please refer to the conference Web site at
http://www.hematology.org.
About Cell Therapeutics, Inc.
Headquartered in
developing an integrated portfolio of oncology products aimed at making cancer
more treatable. For additional information, please visit
http://www.celltherapeutics.com.
Cell Therapeutics, Inc.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
http://www.CellTherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
E: invest@ctiseattle.com
http://www.CellTherapeutics.com/investors
Medical Information Contact:
T: 800.715.0944
E: info@askarm.com
SOURCE Cell Therapeutics, Inc.